- Home
- CRDF vs FDMT Comparison
CRDF vs FDMT Comparison
Compare CRDF & FDMT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRDF
- FDMT
- Stock Information
- Founded
- CRDF 1999
- FDMT 2013
- Country
- CRDF United States
- FDMT United States
- Employees
- CRDF N/A
- FDMT N/A
- Industry
- CRDF Biotechnology: Biological Products (No Diagnostic Substances)
- FDMT Biotechnology: Pharmaceutical Preparations
- Sector
- CRDF Health Care
- FDMT Health Care
- Exchange
- CRDF Nasdaq
- FDMT Nasdaq
- Market Cap
- CRDF 288.7M
- FDMT 268.6M
- IPO Year
- CRDF N/A
- FDMT 2020
- Fundamental
- Price
- CRDF $4.00
- FDMT $4.11
- Analyst Decision
- CRDF Strong Buy
- FDMT Buy
- Analyst Count
- CRDF 4
- FDMT 10
- Target Price
- CRDF $12.00
- FDMT $35.00
- AVG Volume (30 Days)
- CRDF 1.2M
- FDMT 679.8K
- Earning Date
- CRDF 05-01-2025
- FDMT 05-08-2025
- Dividend Yield
- CRDF N/A
- FDMT N/A
- EPS Growth
- CRDF N/A
- FDMT N/A
- EPS
- CRDF N/A
- FDMT N/A
- Revenue
- CRDF $683,000.00
- FDMT $37,000.00
- Revenue This Year
- CRDF N/A
- FDMT $11,029.73
- Revenue Next Year
- CRDF N/A
- FDMT $44.15
- P/E Ratio
- CRDF N/A
- FDMT N/A
- Revenue Growth
- CRDF 39.96
- FDMT N/A
- 52 Week Low
- CRDF $2.01
- FDMT $3.73
- 52 Week High
- CRDF $6.42
- FDMT $36.25
- Technical
- Relative Strength Index (RSI)
- CRDF 48.99
- FDMT 40.31
- Support Level
- CRDF $3.52
- FDMT $3.73
- Resistance Level
- CRDF $4.42
- FDMT $4.34
- Average True Range (ATR)
- CRDF 0.38
- FDMT 0.36
- MACD
- CRDF -0.04
- FDMT 0.02
- Stochastic Oscillator
- CRDF 44.44
- FDMT 33.71
About CRDF Cardiff Oncology Inc.
Cardiff Oncology Inc a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers with the greatest unmet medical need. It is focusing on clinical program in indications such as RAS-mutated metastatic colorectal cancer ("mCRC"), as well as in investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma ("mPDAC"), small cell lung cancer ("SCLC"), and triple negative breast cancer ("TNBC").
About FDMT 4D Molecular Therapeutics Inc.
4D Molecular Therapeutics Inc is a clinical-stage gene therapy company engaged in the development of product candidates using targeted and evolved AAV vectors. It has built a portfolio of gene therapy product candidates focused on three therapeutic areas: Ophthalmology (intravitreal vector) includes 4D-150, 4D-125, 4D-110, and 4D-175; Cardiology (intravenous vector) includes 4D-710, 4D-725, and Pulmonology (aerosol vector) 4D-310.